Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Nebraska for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Nebraska only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Nebraska (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Samer Renno (NPI 1588758312)

Field	Value
Entity Type	Individual
Organization	Samer Renno
Address	6901 N 72nd St
City	Omaha
State	NE
ZIP	68122
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	October 3, 2006

Payer Source	Total Paid
Medicare	$3.2M
Medicaid	$0

Key Findings

This profile is strongly infusion- and oncology-focused: the top revenue drivers are biologic and anticancer injectables and multiple chemotherapy administration codes, with J9271, J9144 and J0897 dominating the mix alongside chemotherapy administration codes such as 96413 and 96416. The presence of high-volume infusion codes and procedural chemotherapy codes indicates the provider operates an outpatient infusion/oncology clinic model that combines office visits and on‑site infusion services.

Revenue is highly concentrated in a small set of drugs: the precomputed top three Medicare codes (J9271, J9144, J0897) account for 68.0% of the provider's total Medicare revenue. In particular J9271 represents $1.4M in revenue and 43.9% of Medicare revenue, while J9144 accounts for $396.7K (12.8%) and J0897 for $349.9K (11.3%), highlighting dependence on a handful of high-revenue products.

This provider is effectively single‑payer Medicare for the record on file: lifetime Medicare revenue is $3.2M and there is no Medicaid billing on file. That payer split implies operational and reimbursement exposure is concentrated in Medicare policy, coverage decisions, and price changes rather than state Medicaid dynamics.

Competitive standing is mixed by product: J9271 ranks #106 of 1841 nationally (94th percentile) and is described as notably above typical national volume, and J0897 ranks in the 97th percentile (#309 of 10057) also notably above typical volume, signaling major national-level participation on those agents. By contrast J9144 sits at the 67th percentile (#191 of 615) and is characterized as typical/unremarkable volume, so the provider is a dominant participant for specific immunotherapy and bone-modifying agents but not uniformly across all specialty drugs.

Several codes are statistical outliers or unusually concentrated relative to peers: J1454 is flagged as an extreme outlier (rank #6 of 422, 99th percentile) and J0640 is also an extreme outlier (rank #18 of 822, 98th percentile), while Q5107 (a bevacizumab biosimilar) ranks #4 of 78 (96th percentile). These outlier signals suggest unusually high utilization of certain newer agents or specific formulations compared with national peers.

Operational volume in evaluation-and-management and infusion-add-on codes supports a high-throughput clinic: 99214 shows 1.1K claims and $92K revenue (3.0% of Medicare revenue) and 99215 has 384 claims and $49.5K revenue (1.6%), while multiple infusion add‑on codes such as 96416 (rank #7 of 117, 95th percentile) and 96367 (97th percentile) are notably above typical national volume. Together these figures point to steady patient follow-up and repeated on-site administrations rather than one-off procedures.

Long tenure on file provides a sustained billing history: the NPI was enumerated on 2006-10-03 (~20 years ago), which aligns with a multi-year Medicare revenue stream totaling $3.2M. That established enrollment supports interpretation of these utilization patterns as an entrenched practice rather than a short-term billing spike.

Concentration risk and reimbursement sensitivity are material business considerations: with $1.4M (43.9%) tied to J9271 and the top three codes making up 68.0% of Medicare revenue, the provider's revenue is sensitive to changes in coverage, pricing, or pathway shifts (including biosimilar uptake such as Q5107). Payers and network managers should view this profile as high-revenue-per-agent and therefore potentially exposed to drug-specific policy changes.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

59 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	31,600	$40	$1.4M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	10,440	$40	$396.7K
J0897	Injection, denosumab, 1 mg	19,440	$20	$349.9K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	8,460	$20	$194.6K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	64,300	$1	$128.6K
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	2,640	$40	$97.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,060	$90	$92K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	210	$340	$71.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	730	$90	$68.6K
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	1,920	$30	$63.4K

Showing 1–10 of 59

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 59 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Nebraska Distribution

Samer Renno — 13 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Nebraska

Full comparison — all codes billed, vs. state median

59 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	30	14,400	$40	$671.6K
J9144	6	10	10,440	$40	$434.6K
Q5107	1	10	5,670	$20	$138.2K
J1459	2	10	3,160	$40	$117.4K
Q5115	2	10	1,920	$30	$73.4K
J0897	3	200	2,040	$20	$62.7K
J0881	1	10	17,260	$1	$54.5K
J1454	1	10	110	$350	$41.5K
J2506	14	20	460	$90	$40.5K
J1439	3	30	25,880	$1	$26.4K

Showing 1–10 of 59

Related Providers

Other providers that share a Tax Identification Number (TIN) with Samer Renno, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Oneworld Community Health Centers, Inc.	NE	Federally Qualified Health Center (FQHC)	$0	$45.1M
Alegent Creighton Clinic	NE	Family Medicine Physician	$0	$43.2M
Alegent Creighton Clinic	IA	Family Medicine Physician	$0	$9.6M
Inaganti Shah	NE	Hematology & Oncology Physician	$2M	$0
Rabih Fahed	NE	Hematology & Oncology Physician	$2M	$0
Timothy Dorius	NE	Internal Medicine Physician	$1M	$0
Logan Helge	NE	Family Nurse Practitioner	$996.6K	$0
Nagendra Natarajan	NE	Hematology & Oncology Physician	$934.8K	$0
Hematology & Oncology Consultants, PC	NE	Hematology & Oncology Physician	$0	$578.6K
James Shehan	NE	Dermatology Physician	$401.5K	$0

Nearby Providers

Other providers in the same ZIP code as Samer Renno, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Alegent Health Immanuel Medical Center	NE	General Acute Care Hospital	$0	$23.7M
Alegent Creighton Health	NE	Internal Medicine Physician	$0	$17.5M
Emergency Clinicians Associates, LLC	NE	Emergency Medical Services (Emergency Medicine) Physician	$0	$6.5M
Alegent Health Immanuel Medical Center	NE	Psychiatric Hospital Unit	$0	$847.8K
Matthew Brumm	NE	Ophthalmology Physician	$593.3K	$0
Abraham Mathews	NE	Hematology & Oncology Physician	$369.1K	$0
Bruce H Brumm Md PC	NE	Ophthalmology Physician	$0	$362.6K
Bruce Baron	NE	Diagnostic Radiology Physician	$282.4K	$0
Charles Schlaepfer	NE	Diagnostic Radiology Physician	$225.4K	$0
Family Ear Nose & Throat Clinic PC	NE	Otolaryngology Physician	$0	$190.5K

Samer Renno — Billing Profile & Reimbursement Data

Sign up for Samer Renno — Billing Profile & Reimbursement Data policy alerts

Samer Renno — Billing Profile & Reimbursement Data

Sign up for Samer Renno — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References